Co-Diagnostics Inc is a biotechnology company that focuses on the development and manufacturing of molecular diagnostic tests used to detect diseases
The company specializes in the design of innovative testing solutions that leverage its proprietary technologies for amplification and detection of nucleic acids. Co-Diagnostics aims to provide accurate and timely diagnostic tools that facilitate the identification of various pathogens, aiding in disease prevention and management. Through its commitment to enhancing diagnostic capabilities, the company supports healthcare providers and public health initiatives.
San Diego, CA -- (SBWIRE) -- 11/18/2022 -- Certain directors of Co-Diagnostics, Inc are under investigation over potential breaches of fiduciary duties.
Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, reminds investors that a class action lawsuit has been filed against Co-Diagnostics, Inc. (“Co-Dx” or the “Company”) (NASDAQCODX) in the United States District Court for the Southern District of New York on behalf of all persons and entities who purchased or otherwise acquired Co-Dx securities between May 12, 2022 and August 11, 2022, both dates inclusive (the “Class Period”). Investors have until October 17, 2022 to apply to the Court to be appointed as lead plaintiff in the lawsuit.
Kaskela Law LLC announces that it is investigating Co-Diagnostics, Inc. (“Co-Diagnostics” or the Company) (NASDAQCODX) on behalf of the Company’s long-term investors. The investigation seeks to determine whether the members of Co-Diagnostics’ board of directors violated the securities laws and/or breached their fiduciary duties in connection with alleged corporate misconduct.
WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Co-Diagnostics, Inc. (NASDAQCODX) between May 12, 2022 and August 11, 2022, both dates inclusive (the “Class Period”), of the important October 17, 2022 lead plaintiff deadline.
San Diego, CA -- (SBWIRE) -- 08/29/2022 -- An investor, who purchased NASDAQ:CODX shares filed a lawsuit against Co-Diagnostics, Inc. over alleged violations of Federal Securities Laws..
Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Co-Diagnostics, Inc. (“Co-Diagnostics” or “the Company”) (NASDAQCODX) and certain of its officers, on behalf of all persons and entities that purchased, or otherwise acquired Co-Diagnostics securities between May 12, 2022 and August 11, 2022, inclusive (the “Class Period”). Such investors are encouraged to join this case by visiting the firm’s site: www.bgandg.com/codx.
Shareholder rights law firm Robbins LLP is investigating Co-Diagnostics, Inc. (NASDAQCODX) and its officers and directors to determine whether they breached fiduciary duties and violated securities laws by misleading investors regarding demand for the Company's Logix Smart™ COVID-19 Test. Co-Dx purports to develop, manufacture, and sell reagents used for diagnostic tests that function via the detection and/or analysis of nucleic acid molecules (DNA or RNA), including robust and innovative molecular tools for detection of infectious diseases, liquid biopsy for cancer screening, and agricultural application.
The Class: Shareholder rights law firm Robbins LLP reminds investors that a shareholder filed a class action on behalf of all persons and entities that purchased Co-Diagnostics, Inc. (NASDAQCODX) securities between May 12, 2022 and August 11, 2022, for violations of the Securities Exchange Act of 1934. Co-Dx purports to develop, manufacture, and sell reagents used for diagnostic tests that function via the detection and/or analysis of nucleic acid molecules (DNA or RNA), including robust and innovative molecular tools for detection of infectious diseases, liquid biopsy for cancer screening, and agricultural application.
Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, announces that a class action lawsuit has been filed against Co-Diagnostics, Inc. (“Co-Dx” or the “Company”) (NASDAQCODX) in the United States District Court for the Southern District of New York on behalf of all persons and entities who purchased or otherwise acquired Co-Dx securities between May 12, 2022 and August 11, 2022, both dates inclusive (the “Class Period”). Investors have until October 17, 2022 to apply to the Court to be appointed as lead plaintiff in the lawsuit.
The Class: Shareholder rights law firm Robbins LLP informs investors that a shareholder filed a class action on behalf of all persons and entities that purchased Co-Diagnostics, Inc. (NASDAQCODX) securities between May 12, 2022 and August 11, 2022, for violations of the Securities Exchange Act of 1934. Co-Dx purports to develop, manufacture, and sell reagents used for diagnostic tests that function via the detection and/or analysis of nucleic acid molecules (DNA or RNA), including robust and innovative molecular tools for detection of infectious diseases, liquid biopsy for cancer screening, and agricultural application.
The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Co-Diagnostics, Inc. (“Co-Diagnostics” or “the Company”) (NASDAQCODX) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.
